canertinib has been researched along with Carcinoma, Non-Small Cell Lung in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, S; Ding, J; Ding, K; Geng, M; Liu, Y; Lu, X; Luo, J; Pei, D; Ren, X; Tu, Z; Xu, S; Xu, T; Xu, Y; Zhang, L; Zhang, Z | 1 |
| Almaden, C; Bailey, S; Baxi, S; Behenna, D; Cheng, H; Cho-Schultz, S; Dalvie, D; Dinh, DM; Edwards, MP; Feng, JL; Ferre, RA; Gajiwala, KS; Hemkens, MD; Jackson-Fisher, A; Jalaie, M; Johnson, TO; Kania, RS; Kath, JC; Kephart, S; Lafontaine, J; Liu, KK; Liu, Z; Lunney, B; Matthews, J; Murray, BW; Nagata, A; Nair, SK; Niessen, S; Ornelas, MA; Orr, ST; Pairish, M; Planken, S; Ren, S; Richter, D; Ryan, K; Sach, N; Shen, H; Smeal, T; Solowiej, J; Sutton, S; Tran, K; Tseng, E; Vernier, W; Walls, M; Wang, S; Weinrich, SL; Xin, S; Xu, H; Yin, MJ; Zhou, R; Zientek, M | 1 |
| Almaden, C; Bailey, S; Ballard, TE; Behenna, DC; Bernier, L; Cheng, H; Cho-Schultz, S; Dalvie, D; Deal, JG; Dinh, DM; Edwards, MP; Ferre, RA; Gajiwala, KS; Hemkens, M; Johnson, TO; Kania, RS; Kath, JC; Lafontaine, J; Liu, L; Luo, Y; Matthews, J; Murray, BW; Nagata, A; Nair, SK; Niessen, S; Orr, ST; Pairish, M; Planken, S; Sach, NW; Shen, H; Shi, M; Solowiej, J; Tran, K; Tseng, E; Vicini, P; Wang, Y; Weinrich, SL; Xin, S; Zhang, C; Zhou, R; Zientek, M | 1 |
| Chen, J; Li, W; Ouyang, L; Shuai, W; Tan, L; Wang, C; Wang, G; Wang, X; Wang, Y; Zhang, J; Zhang, Z | 1 |
| Bao, J; Chen, X; DeCook, R; Ding, D; Kobel, M; Kopecky, BJ; Li, H; Ou, HC; Qian, Y; Sun, Z; Tang, J | 1 |
| Belani, CP | 1 |
| Baselga, J; Hammond, LA | 1 |
| Lorusso, PM | 1 |
| Sequist, LV | 1 |
| Bitran, JD; Burnett, D; Chiappori, AA; Eiseman, I; Ellis, PM; Hamm, JT; Lenehan, P; Lovalvo, J; Olson, S; Zinner, RG | 1 |
| Bonomi, PD; Butts, CA; Chiappori, AA; Cohen, RB; Crino, L; Dasse, K; Eiseman, IA; Jänne, PA; Lenehan, PF; Olson, SS; Sheeran, M; von Pawel, J; Yeap, BY | 1 |
4 review(s) available for canertinib and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Morpholines; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Quinolines | 2010 |
HER-targeted tyrosine-kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2002 |
Phase I studies of ZD1839 in patients with common solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Morpholines; Organic Chemicals; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines | 2007 |
2 trial(s) available for canertinib and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Odds Ratio; Paclitaxel; Patient Selection; Probability; Prognosis; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome; United States | 2006 |
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Morpholines; Survival Rate | 2007 |
5 other study(ies) available for canertinib and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Methionine; Mice; Mice, Nude; Mice, SCID; Molecular Conformation; Mutation; Neoplasm Transplantation; Pyrimidines; Quinazolines; Structure-Activity Relationship; Threonine; Transplantation, Heterologous | 2012 |
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Discovery; ErbB Receptors; Humans; Lung Neoplasms; Models, Molecular; Molecular Structure; Mutant Proteins; Mutation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 2016 |
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants
Topics: Acrylamides; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dogs; Drug Design; ErbB Receptors; Halogenation; Humans; Lung; Lung Neoplasms; Mice; Models, Molecular; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Pyrrolidines; Rats | 2017 |
Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy.
Topics: Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Canertinib induces ototoxicity in three preclinical models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Screening Assays, Antitumor; Ear; Electrophysiology; ErbB Receptors; Female; Hair Cells, Auditory, Outer; Hearing; Hearing Loss; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Morpholines; Neuregulin-1; Signal Transduction; Zebrafish | 2015 |